Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
- Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic EsophagitisEupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”).
- Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerGlobal Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer
- Dental Equipment Market Forecasts Growth from $8.31B (2026) to $11.48B by 2031, Profiling Envista, Carestream Dental, Nakanishi & Dentsply SironaThe global dental equipment market is projected to grow from USD 8.31 billion in 2026 to USD 11.48 billion by 2031, registering a 5.5% CAGR. Growth is driven by rising oral health disorders, demand for cosmetic and preventive dentistry, dental tourism, and adoption of digital imaging, CAD/CAM, intraoral scanners, laser dentistry, and 3D printing. Therapeutic dental equipment will hold the largest market share, while hospitals and clinics remain the leading end users. The US is expected to record North America’s fastest growth. Key players include Dentsply Sirona, Planmeca, Align Technology, Envista, Carestream Dental, Nakanishi, and A-dec.
- Esophageal Cancer - 7MM Market Insights, Epidemiology, Competitive Landscape, and Forecast - 2036 | 6.0% CAGR Fueled by Immunotherapy and Precision OncologyImmunotherapy uptake, biomarker-led precision care and next-generation targeted agents are reshaping treatment, while late diagnosis and drug resistance sustain unmet need.
- transcosmos inc.Toward a new era of pharmaceutical education: TUPLS and transcosmos launch a co-development project to build an AI-powered, dialogue-based learning platformAdvancing support for foundational learning, patient communication, and continuous learning in clinical pharmaceutical education TOKYO, Sept. 30, 2026/PRNewswire/ -- The Tokyo University of Pharmacy and Life Science (Location: Tokyo, Japan; President: Yoshihiro Mimaki; TUPLS) and...
- Bone Neoplasms - Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and ADC Pipelines Unlock Strategic Growth Opportunities Through 2036Target unmet needs in durable, low-toxicity therapies and use 7MM uptake, access, pipeline and competitive insights to refine development, launch and market-entry strategies.
- Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell CancersHummingbird Bioscience announced that the first patient has been dosed in Phase II trial of HMBD-001 and cetuximab in advanced squamous cell cancers.
- Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth OpportunitiesRising cancer survival fuels demand for targeted, radiopharmaceutical and combination therapies addressing tumor growth and the bone microenvironment.
- North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion OpportunityTarget clinical and biopharma segments, forge strategic partnerships, and differentiate with scalable, low-toxicity delivery solutions.
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape CarePrioritize HPV16-targeted vaccines, checkpoint inhibitor combinations and biomarker-led patient selection to overcome resistance and capture underserved HNSCC segments.
- Artificial Intelligence (AI) in Life Sciences Market: Trends and Forecast to 2040 | Market to Reach USD 73.05 Billion at 20% CAGR as Drug Discovery and Precision Medicine ScaleAI boosts life sciences ROI by accelerating drug discovery, reducing R&D costs, optimizing clinical trials and enabling precision medicine through strategic tech partnerships.